DVA - DaVita Inc.

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.

Oct 15, 2026 05:00 AM • prnewswire.com

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.

Oct 09, 2026 03:01 PM • zacks.com

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.

Oct 09, 2026 11:06 AM • seekingalpha.com

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.

Oct 09, 2026 06:51 AM • zacks.com

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and southeastern United States, DaVita has activated its emergency response plan to help patients continue receiving life-sustaining dialysis care and to support communities preparing for severe weather. The storm is expected to bring heavy rainfall, flooding, storm surge and high winds across portions of the region.

Oct 08, 2026 12:00 PM • prnewswire.com

3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs

American Express is the last remaining credit card stock in Berkshire's portfolio. The New York Times Company is bucking the trend of the struggling newspaper industry.

Oct 06, 2026 02:00 AM • fool.com

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.

Oct 02, 2026 03:00 PM • zacks.com

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

DaVita reported double-digit EPS growth in the second quarter. Berkshire Hathaway owns roughly 45% of DaVita stock.

Sep 29, 2026 01:43 AM • fool.com

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

Sep 24, 2026 03:00 PM • zacks.com

3 Surging Stocks That Don't Need the AI Boom to Keep Winning

With AI companies—and related chip stocks—driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momentum it seems to have. Fortunately, a number of non-AI stocks have stood out for their strong performance throughout the first part of 2026.

Sep 21, 2026 05:10 AM • marketbeat.com

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

Sep 16, 2026 03:00 PM • zacks.com

Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You

President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.

Sep 16, 2026 08:13 AM • benzinga.com

A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32

On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49

Sep 14, 2026 03:53 PM • gurufocus.com

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.

Sep 09, 2026 09:11 AM • zacks.com

Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Sep 03, 2026 08:31 AM • zacks.com

Do Options Traders Know Something About DaVita Stock We Don't?

Investors need to pay close attention to DVA stock based on the movements in the options market lately.

Sep 03, 2026 06:00 AM • zacks.com

4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds

An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.

Aug 28, 2026 08:46 AM • zacks.com

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

In fact, it's a healthcare company. It is a strong player in its chosen niche.

Aug 27, 2026 11:03 AM • fool.com

DVA & Humana Expand Value-Based Care for Kidney Disease Patients

DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.

Aug 26, 2026 08:31 AM • zacks.com

Alebund Pharmaceuticals Announces 2026 Interim Results

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Aug 26, 2026 02:47 AM • prnewswire.com

DaVita price target lowered to $215 from $250 at Truist

$215.00 (was $179.93)

Truist Financial

Aug 07, 2026 10:08 AM • TheFly

TD Cowen Upgrades DaVita (DVA) to Buy

$220.00 (was $180.67)

Oppenheimer

Aug 07, 2026 05:31 AM • StreetInsider

TD Cowen Upgrades DaVita (DVA) to Buy

$220.00 (was $180.67)

Raymond James

Aug 07, 2026 05:31 AM • StreetInsider

DaVita price target raised to $265 from $220 at Deutsche Bank

$265.00 (was $185.53)

Pito Chickering · Deutsche Bank

Aug 05, 2026 09:18 AM • TheFly

DaVita price target raised to $224 from $218 at Barclays

$224.00 (was $227.99)

Andrew Mok · Barclays

Aug 05, 2026 05:08 AM • TheFly

DaVita price target raised to $250 from $205 at Truist

$250.00 (was $235.58)

Truist Financial

Jul 14, 2026 07:49 AM • TheFly

DaVita price target raised to $270 from $235 at UBS

$270.00 (was $229.48)

UBS

Jul 10, 2026 06:17 AM • TheFly

DaVita price target raised to $218 from $194 at Barclays

$218.00 (was $234.31)

Barclays

Jul 08, 2026 06:20 AM • TheFly

DaVita price target raised to $205 from $158 at Truist

$205.00 (was $194.38)

Truist Financial

May 08, 2026 07:56 AM • TheFly

DaVita price target raised to $194 from $158 at Barclays

$194.00 (was $193.88)

Andrew Mok · Barclays

May 07, 2026 05:46 AM • TheFly

DaVita upgraded to Buy from Hold at Deutsche Bank

$220.00 (was $157.04)

Pito Chickering · Deutsche Bank

May 06, 2026 04:37 AM • TheFly

DaVita price target raised to $158 from $128 at Truist

$158.00 (was $144.41)

Truist Financial

Feb 05, 2026 10:04 AM • TheFly

DaVita price target raised to $190 from $186 at UBS

$190.00 (was $134.73)

UBS

Feb 04, 2026 06:34 AM • TheFly

DaVita price target raised to $158 from $143 at Barclays

$158.00 (was $111.19)

Barclays

Feb 03, 2026 05:24 AM • TheFly

DaVita price target lowered to $143 from $149 at Barclays

$143.00 (was $126.56)

Barclays

Oct 30, 2025 06:20 AM • TheFly

DaVita price target lowered to $140 from $148 at Truist

$140.00 (was $123.36)

David MacDonald · Truist Financial

Oct 14, 2025 09:20 AM • TheFly

DaVita price target lowered to $149 from $160 at Barclays

$149.00 (was $127.89)

Andrew Mok · Barclays

Oct 09, 2025 05:48 AM • TheFly

DaVita price target lowered to $148 from $164 at Truist

$148.00 (was $129.54)

David MacDonald · Truist Financial

Aug 08, 2025 11:01 AM • TheFly

Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%

$184.00 (was $142.40)

Lisa Bedell Clive · Bernstein

Feb 21, 2025 02:00 AM • Benzinga

DaVita price target raised to $145 from $139 at BofA

$145.00 (was $133.53)

Kevin Fischbeck · Bank of America Securities

Aug 07, 2024 06:09 AM • TheFly